- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Riverain’s Chest X-ray Software
Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays.
Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays, the company announced.
ClearRead + Confirm also allows radiologists to confirm the proper placement of tubes, lines, and wires, the company said. Portable chest X-ray machines, typically used to confirm line and tube placement, doesn’t have high quality images, and radiologists spend time adjusting the machines to make the edges stand out.
This software increases the readability of the chest X-ray by selectively increasing contrast and suppressing the clavicles and ribs in the image, removing items that could obscure visibility of the lines and tubes.
A Georgetown University reader study assessed the time it took radiologists to locate PICC lines, nasogastric tubes, and wires that conduct or measure electrical impulses. Ten radiologists reviewed 334 X-rays with and without the software, and the software reduced the reading time by 19 percent, according to the company.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
